June, 5438+February, 2000, with the approval of Jiangsu Provincial People's Government [Su (2000) No.213], Hengrui Group, Shanghai Lianchuang, etc. 10 as the sponsors, Lianyungang Kangyuan Pharmaceutical Co., Ltd. took June, 2000 as 5438+ 10. The company now produces 86 varieties in 8 dosage forms, such as hard capsules, soft capsules and oral liquids, with an annual output of 654.38 billion tablets, 500 million capsules, 85 million soft capsules, 500 tons of granules, 50 million oral liquids and 654.38 billion concentrated pills. The main products are Guizhi Fuling Capsule, Tianshu Capsule, Kanggu Zengsheng Capsule, Xiaochaihu Granule and Jinzhen Oral Liquid. Our company pays attention to scientific research and new product development, with new drug certificates 10 and 5 national second-class protected varieties of traditional Chinese medicine. The company is a key high-tech enterprise of the National Torch Plan and an advanced quality management enterprise in China.
The company insists on scientific research and innovation as the guide, and constantly enhances the independent innovation strength of enterprises. The enterprise has set up a postdoctoral research center, an academician workstation in Jiangsu Province and Kangyuan Institute of Modern Chinese Medicine, with a research team of more than 80 people, including 6 postdoctoral researchers, 2 doctors and more than 80 masters. We have jointly established more than ten laboratories with the Institute of Pharmacology of China Academy of Medical Sciences, Shanghai Institute of Organic Chemistry of Chinese Academy of Sciences, dalian polytechnic university and other scientific research institutes, and established an innovative drug research and development company in the United States. Our independent innovation capability and the number of invention patents granted in the same industry rank among the top in domestic counterparts. In 2002, Kangyuan Pharmaceutical was approved to set up a postdoctoral research center. In 2005, the company's R&D center was recognized as a national enterprise technology center. 20 10 10 Kangyuan Research Institute was approved by the Ministry of Science and Technology to build the "State Key Laboratory of Chinese Medicine Pharmaceutical Technology" and entered the national team of Chinese medicine innovation system.
Kangyuan Pharmaceutical has the largest intelligent Chinese herbal medicine extraction production line in China, with an annual processing capacity of raw medicinal materials 1 10,000 tons; Has passed the national GMP certification preparation workshop, well-equipped preparation center, quality inspection center, power center and intelligent management center. It has thirteen most advanced production lines, including hard capsules, soft capsules, small-volume injections and freeze-dried powder injections. The annual output is 654.38+0.2 billion hard capsules, 340 million soft capsules, 654.38+0 billion oral liquids, 500 million small-volume injections, 6 million freeze-dried powder injections and 6 million freeze-dried powder injections.
Kangyuan Pharmaceutical has made every effort to promote professional and academic marketing, established a high-quality and professional marketing team with more than 1.600 people, established 34 sales branches and more than 226 central offices in 29 provinces and cities across the country, and established long-term and stable business relations with 46 pharmaceutical commercial companies nationwide, covering nearly 7,000 medical units above the county level. Among the listed products, there are 2 large-scale varieties, 3 varieties with sales income of 200-500 million yuan and 3 varieties with sales income of1-200 million yuan.